SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

Despite a slight revenue increase and optimistic guidance, the company's financial health is concerning due to increased operating expenses, a decline in gross margin, and extended sales cycles. The Q&A reveals confidence in future growth but lacks specifics on product advancements and market expansion. The transition to wholesale pricing and sales tax exposure add further risk. Overall, the financial metrics and uncertainties suggest a negative stock price movement in the short term.

Key Financial Performance

Revenue $9.6 million for Q1 2026, an increase of 3% compared to $9.3 million for the same period in 2025. The growth was on the low end of guidance and was driven by consumables utilization growth.

Gross Margin 77.3% for Q1 2026, a decrease of 177 basis points year-over-year. This was driven by a decrease in pricing on UltraMIST systems and applicators due to wholesale pricing to resellers.

Operating Loss $1.1 million for Q1 2026, a $1.7 million swing compared to operating income of $0.6 million in Q1 2025. This was due to increased operating expenses, including higher noncash stock-based compensation, payroll-related expenses, R&D investments, and nonrecurring expenses.

Operating Expenses $8.6 million for Q1 2026, an increase of $1.8 million compared to $6.8 million in Q1 2025. The increase was driven by higher stock-based compensation, payroll expenses, R&D investments, and sales and marketing costs.

Net Loss $1.4 million for Q1 2026, an improvement of $4.7 million compared to a net loss of $6.1 million in Q1 2025. The improvement was primarily due to the absence of a $4.9 million noncash loss in the change in fair value of derivative liabilities and lower interest expenses.

EBITDA Negative $0.6 million for Q1 2026. Adjusted EBITDA was positive $1.1 million, compared to $2.3 million in Q1 2025. The decline reflects planned investments in headcount, R&D, and commercial expansion.

Consumables Utilization Grew 22% year-over-year and 4% sequentially from Q4 2025, contributing to revenue growth.

Cash and Cash Equivalents $10.8 million as of March 31, 2026, compared to $24.6 million as of December 31, 2025.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

UltraMIST system and applicators: Achieved record unit sales in Q1, driven by increased customer usage and new customer acquisitions. However, revenue was impacted by a shift to wholesale pricing for resellers.

Market expansion in advanced wound care: Expanded presence in hospitals, wound centers, physicians' offices, and long-term care facilities. Renewed interest in mobile wound care despite challenges, with consolidation favoring larger, more sophisticated providers.

Operational performance: Achieved highest Q1 revenues in company history at $9.6 million, a 3% increase year-over-year. Consumables utilization grew 22% year-over-year. Gross margin decreased due to wholesale pricing.

Cost management: Operating expenses increased due to investments in R&D, headcount, and marketing. Despite this, net loss improved significantly year-over-year, and adjusted EBITDA remained positive.

Strategic focus on mobile wound care: Focused on adapting to market changes, including consolidation and tighter CMS standards. Emphasized working with fewer, larger providers for better engagement and efficiency.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Market Freeze and CMS Pricing Impact: The advanced wound care market experienced a significant freeze in January due to unexpected CMS pricing changes for skin substitutes. This caused financial stress among practitioners and elevated churn rates, impacting the company's operations and sales cycles.

Shift to Wholesale Pricing: Transition of long-standing distributors to resellers led to a shift from retail to wholesale pricing, reducing revenue and average selling prices (ASPs), despite record unit sales.

Mobile Wound Care Challenges: The mobile wound care sector is undergoing consolidation due to tightened CMS and MAC documentation standards, lower reimbursement rates, and high operational costs. Rural areas face additional challenges with low pay rates and high travel costs, potentially limiting patient access to care.

Sales Tax Exposure: The company is addressing sales tax issues through voluntary disclosure agreements, but this remains a potential financial risk.

Increased Operating Expenses: Operating expenses rose significantly due to higher payroll, R&D investments, and nonrecurring costs related to restatement work, impacting profitability.

Extended Sales Cycles: Sales cycles remain prolonged as providers face financial uncertainties and cautious capital budgeting due to CMS audits and clawbacks.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Q2 2026 Revenue Growth: Guidance for Q2 2026 is 10% to 15% year-on-year growth, representing $11.1 million to $11.6 million for the quarter.

Full-Year 2026 Revenue Guidance: Maintaining guidance of $51 million to $55 million for the year.

Market Recovery Expectations: The market freeze is beginning to thaw, with expectations for further improvement as providers gain clarity on their finances and capital budgets.

Mobile Wound Care Trends: Mobile wound care remains a critical focus area, with consolidation expected due to tighter CMS and MAC standards and the need for higher route density and revenue per practitioner.

Rural Market Challenges: Concerns about rural areas due to lower pay rates and high travel times; potential need for reindexing or payment for travel time to address these challenges.

Second Half 2026 Optimism: Optimistic about the second half of 2026 due to ongoing evaluations with large systems that could lead to significant opportunities.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:You grew 3% year-over-year in Q1, expecting to grow 10% to 15% in Q2, and kept your guidance at 16% to 25% growth for the year. Can you provide more color on what gives you confidence in the back half of the year?

A:Morgan Frank explained that the business is traditionally seasonal, with the second half of the year typically showing a 48% increase over the first half. He noted that this year, due to suppressed performance in the first half, there is potential for even better growth in the second half. He also highlighted increased engagement with large and national accounts, as well as positive feedback and adoption of UltraMIST after initial trials, as key drivers for confidence in the back half.

Q:Are you excited about any advancements you're making to the UltraMIST product over the next 24 months?

A:Morgan Frank confirmed that they are working on incremental improvements to the existing product, as well as exploring adjacent areas. However, he stated that they are not ready to discuss these advancements publicly at this time.

Q:Are there any evidence-based trials being conducted with large customers or groups to provide more evidence for entering new market areas?

A:Morgan Frank confirmed that they are working with users to generate data on cost-effectiveness and validate additional use cases for UltraMIST. He mentioned that UltraMIST has a broad label and hinted at upcoming papers and white papers that will outline new use cases, potentially expanding its applications.

Q:Review of Unclear Management Responses

A:Morgan Frank avoided providing specific details about advancements to the UltraMIST product and adjacent areas, stating that they are not ready to discuss these publicly. Additionally, while he mentioned ongoing data generation and upcoming papers, he did not provide concrete timelines or specifics about the trials or new market areas.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

SNWV Transcript

SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript

Unknown5-13

SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript

Positive3-27

The earnings call highlights a strong financial performance with a 25% revenue increase, improved gross margins, and a shift from net loss to net income. The positive cash flow indicates solid financial health. Despite the absence of strategic and operational updates, the financial metrics suggest a positive outlook. However, the lack of strategic guidance and acknowledgment of risks tempers the sentiment slightly. The overall impact is likely positive, given the financial turnaround and margin improvements.

SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript

Positive11-7

The earnings call summary indicates a focus on cost efficiency, marketing expansion, and a conservative revenue guidance due to past anomalies. The Q&A section reveals positive sentiment towards sales strategies and potential growth, despite some uncertainties in adoption timelines. Key factors like improved financial footing and inbound interest from distributors suggest a positive outlook. However, the lack of international expansion and cautious revenue guidance temper expectations. Overall, the sentiment is positive, with a potential stock price increase of 2% to 8% over the next two weeks.

SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript

Unknown10-6

The earnings call reveals several negative aspects, including a miss on Q3 revenue guidance, market uncertainty impacting growth, and challenges in forecasting. Despite some positive developments like a record September revenue and improved sales pipeline, the downward adjustment of annual revenue guidance and regulatory risks weigh heavily. The Q&A section reflects cautious optimism but lacks specific details, and the refusal to provide detailed guidance further dampens sentiment. These factors suggest a likely stock price decline in the range of -2% to -8%.

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.